Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

36.23 +2.22 (+6.53%)
Streaming Delayed Price Updated: 1:34 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 Next >
Ionis Pharmaceuticals, inc (IONS) Q3 2021 Earnings Call Transcript
IONS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
Why Ionis Pharmaceuticals Stock Is Down 13% This Week
An experimental treatment for amyotrophic lateral sclerosis missed the mark in a phase 3 trial. 
Via The Motley Fool
46 Biggest Movers From Yesterday
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.... 
Via Benzinga
Ionis Stock Collapses On Another 'Misstep' As Biogen-Partnered ALS Drug Flops
Biogen and Ionis' approach to Lou Gehrig's disease missed its key goal. 
Via Investor's Business Daily
Biogen's Antisense Candidate Flunks In Late-Stage Neurodegenerative Disorder Trial
Biogen Inc (NASDAQ: BIIB) has announced topline results from its Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug for superoxide... 
Via Benzinga
PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder
The Brazilian Health Regulatory Agency has approved PTC Therapeutics Inc's (NASDAQ: PTCT) Waylivra (volanesorsen) as the first treatment for familial... 
Via Benzinga
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Ionis Pharmaceuticals, inc (IONS) Q2 2021 Earnings Call Transcript
IONS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline data from a Phase 1b study of BIIB080/IONIS-MAPTRx in mild... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Bicycle, Ionis To Develop Targeted Oligonucleotide Therapeutics
Bicycle Therapeutics plc (NASDAQ: BCYC) announced that Ionis Pharmaceuticals Inc (NASDAQ: IONS) has exercised its option and entered into an exclusive... 
Via Benzinga
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical... 
Via Benzinga
3 Cathie Wood Stocks You Can Buy for Less Than $50
You can get a lot of bang for the buck with these picks. 
Via The Motley Fool
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
14 Biotech Stocks To Watch Over The Next 6 Months
Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:... 
Via Benzinga
3 Stocks Wall Street Thinks Will Skyrocket 50% or More
Analysts view all three as rebound candidates. 
Via The Motley Fool
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3) BioCryst Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 27) BioCryst Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Thursday
On Thursday morning, 9 companies achieved new lows for the year. Noteables: The largest company by market cap to set a new 52-week low was Clorox (NYSE:CLX). The... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 20 companies set new 52-week lows. Interesting Facts: The largest company in terms of market cap to set a new 52-week low was Ionis... 
Via Benzinga
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 16 companies set new 52-week lows. Noteworthy Points: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
The Fight Against Alzheimer's Reaches A Moment Of Truth For Biogen, Other Biotech Stocks
The FDA will soon review aducanumab, possibly the first new Alzheimer's treatment in years. Stakes are high for Biogen stock — and other biotech stocks too. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.